| News
BioMedPartners closes new venture capital fund
06.03.2018
Basel-based venture capitalist firm BioMedPartners has closed its new venture capital fund BioMedInvest III at 100 million Swiss francs. The fund will help drive growth in the Swiss life science cluster by investing in private early-to-mid-stage companies.

BioMedPartners
Main investors in the BioMedInvest III healthcare venture capital fund are the European Investment Fund (EIF) and the Berner Kantonalbank (BEKB). According to Markus Hosang, General Partner at BioMedPartners, his company also succeeded in gaining the Basellandschaftliche Kantonalbank (BLKB) and several important individuals as new investors.
“We are proud of having established BioMedPartners as a leading venture group and early-stage life science investor in Europe over the last 15 years since its inception,” added Thomas Möller, General Partner at BioMedPartners. “The successful closing of our third equity venture fund is also a major milestone for the future growth of the Life Science Cluster in Switzerland.”
The Basel-based company will invest 100 million Swiss francs in 12 to 15 biopharmaceutical, medical device and diagnostics companies. It will also take an active role in these companies by providing its expertise and access to its network of industry experts and scientific leaders.
The fund’s focus is on Swiss companies as well as those from neighbouring countries. For instance, its first three investments are: Allecra Therapeutics, a French antibiotics company based in the Basel area, Amal Therapeutics in Geneva, and the German biotech company Cardior Pharmaceuticals.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Evolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...
Read MoreRecord figure for startups in the Basel Area
Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...
Read MoreNoema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....
Read MoreWhy CDMO companies choose the Basel Area as their location
Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...
Read MoreBasel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...
Read MoreAriceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...
Read MoreRocketVax raises fresh capital
The Basel-based biotech startup RocketVax has successfully closed another financing round. This additional funding will primarily be used to further...
Read MoreClinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...
Read MoreKUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read More